Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

This study is testing whether adding targeted radiation therapy (to all cancer sites, not just the chest) to the immunotherapy drug durvalumab can improve outcomes in people with small cell lung cancer (SCLC) that has spread to only a few locations in the body (oligometastatic disease) and responded to initial chemotherapy. **You may be eligible if...** - You have been newly diagnosed with extensive-stage small cell lung cancer that has spread to up to four separate tumor sites - Your cancer has responded to (or stabilized with) two initial rounds of chemotherapy combined with durvalumab - Your lung function is adequate (FEV1 at least 1.3 liters) - Your blood counts, liver, and kidney function are adequate - Your overall health is acceptable (ECOG 0–1) **You may NOT be eligible if...** - You have had other prior cancer treatments besides the initial two rounds of chemotherapy and durvalumab - You have an active autoimmune disease - You have active hepatitis B, C, or HIV - You have had a recent major surgery within 4 weeks - You are pregnant or breastfeeding - You have leptomeningeal disease (cancer spread to the lining of the brain and spinal cord) Talk to your doctor to see if this trial is right for you.